Company: JUNS
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001261
Chunk: 440

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 11
Chunk 440
---
 XBRL Taxonomy Extension Labels Linkbase
  
    101.PRE*
     
    Inline
    XBRL Taxonomy Extension Presentation Linkbase
  
    104*
     
    Cover
    Page Interactive Data File (embedded within the Inline XBRL document)

*
Filed herewith.

**
Furnished herewith.

†
Management contracts, compensation plans and arrangements.

Item
16. Form 10-K Summary

Not
applicable.

124

JUPITER
NEUROSCIENCES, INC.

Index
to Financial Statements

    Report
    of Independent Registered Public Accounting Firm Assurance Dimensions, LLC PCAOB ID: 5036
    F-2

    Balance Sheets as of December 31, 2024 and 2023
    F-3

    Statements of Operations for the Years Ended December 31, 2024 and 2023
    F-4

    Statements
    of Changes in Stockholders’ Equity (Deficit) for the Years Ended December 31, 2024 and 2023
    F-5

    Consolidated Statements of Cash Flows for the Years Ended December 31, 2024 and 2023
    F-6

    Notes to Financial Statements
    F-7

F-1

REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To
the Stockholders and Board of Directors of

Jupiter
Neurosciences, Inc

Opinion
on the Financial Statements

We
have audited the accompanying balance sheets of Jupiter Neurosciences, Inc, (the Company) as of December 31, 2024 and 2023, and the related
statements of operations, stockholders’ equity (deficit), cash flows for each of the years in the two-year period ended December
31, 2024, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present
fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations
and its cash flows for each of the years in the two-year period ended December 31, 2024, in conformity with accounting principles generally
accepted in the United States of America.

Explanatory
Paragraph – Going Concern

The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note
2 to the